IUPAC/Chemical Name
3-(2-((3-(2-carboxyethyl)-5-(((2S,3R,4R)-3-ethyl-4-methyl-5-oxopyrrolidin-2-yl)methyl)-4-methyl-1H-pyrrol-2-yl)methyl)-5-(((2S,3R,4R)-4-ethyl-3-methyl-5-oxopyrrolidin-2-yl)methyl)-4-methyl-1H-pyrrol-3-yl)propanoic acid
InChi Key
VKGRRZVYCXLHII-OLFWPHQKSA-N
InChi Code
1S/C33H48N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h16,19-21,26-27,34-35H,7-15H2,1-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/t16-,19-,20-,21-,26+,27+/m1/s1
SMILES Code
CC[C@@H]1[C@@H](C)C(=O)N[C@H]1CC2=C(C)C(CCC(O)=O)=C(CC3=C(CCC(O)=O)C(C)=C(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)N3)N2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
596.77
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Tripathi N, Jialal I. Conjugated Hyperbilirubinemia. 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32965843.
2: Gallo E, Pich P, Ricco G, Saglio G, Camaschella C, Mazza U. The relationship between anemia, fecal stercobilinogen, erythrocyte survival, and globin synthesis in heterozygotes for beta-thalassemia. Blood. 1975 Nov;46(5):693-8. PMID: 1174704.
3: LOWRY PT, ZIEGLER NR, CARDINAL R, WATSON CJ. The conversion of N15-labeled mesobilirubinogen to stercobilinogen by fecal bacteria. J Biol Chem. 1954 Jun;208(2):543-8. PMID: 13174565.
4: BAUMGARTEL T. Zum Nachweis der biologischen Bilirubinderivate; Urobilinogen und Stercobilinogen [For the detection of biological bilirubin derivatives; Urobilinogen and stercobilinogen]. Med Klin. 1947 Mar 21;42(6):231-3. German. PMID: 20296557.
5: Vítek L, Majer F, Muchová L, Zelenka J, Jirásková A, Branný P, Malina J, Ubik K. Identification of bilirubin reduction products formed by Clostridium perfringens isolated from human neonatal fecal flora. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Apr 3;833(2):149-57. doi: 10.1016/j.jchromb.2006.01.032. Epub 2006 Feb 28. PMID: 16504607.
6: Feng X, Wang M, Wen S, Hu L, Lan Y, Xu H. Lactiplantibacillus plantarum P101 Alleviated Alcohol-Induced Hepatic Lipid Accumulation in Mice via AMPK Signaling Pathway: Gut Microbiota and Metabolomics Analysis. Probiotics Antimicrob Proteins. 2024 Oct 10. doi: 10.1007/s12602-024-10373-6. Epub ahead of print. PMID: 39388022.
7: BAAR HS. The life span of red blood corpuscles in erythronophthisis including a method for the estimation of faecal stercobilinogen. Acta Haematol. 1952 Jan;7(1):17-26. doi: 10.1159/000204028. PMID: 14902320.
8: Sekera ER, Rudolph HL, Carro SD, Morales MJ, Bett GCL, Rasmusson RL, Wood TD. Depletion of Stercobilin in Fecal Matter from a Mouse Model of Autism Spectrum Disorders. Metabolomics. 2017 Nov;13(11):132. doi: 10.1007/s11306-017-1277-9. Epub 2017 Oct 3. PMID: 29147105; PMCID: PMC5685184.
9: Fassati P, Fassati M. O původu a vylucování mezobilirubinogenu a sterkobilinogenu na základĕ vysetrování normální lidské zluci [The origin and elimination of mesobilirubinogen and stercobilinogen based on the examination of normal human bile]. Cas Lek Cesk. 1965 Oct 15;104(41):1125-9. Czech. PMID: 5853518.
10: BERMAN J. Význam kvantitativnäho vy6set6renä porfyrinu a sterkobilinogenu v mo6ci a ve stolici u jaternĭch chorob [Importance of quantitative determination of urinary and fecal porphyrins and stercobilinogen in liver diseases]. Cesk Gastroenterol Vyz. 1955 Mar;9(1):25-31. Czech. PMID: 14379261.
11: Djerassi LS, Vitany L. Haemolytic episode in G6 PD deficient workers exposed to TNT. Br J Ind Med. 1975 Feb;32(1):54-8. doi: 10.1136/oem.32.1.54. PMID: 1125128; PMCID: PMC1008022.
